Company news

MediWound Ltd. news in 2023

MediWound Ltd.'s news releases, calls and decks from 2023, newest first.

View company

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

December 27, 2023

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

December 20, 2023

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

November 20, 2023

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

November 20, 2023

MediWound to Report Third Quarter 2023 Financial Results

November 13, 2023

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

November 12, 2023

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

November 7, 2023

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

October 10, 2023

MediWound Deploys NexoBrid® for Emergency Supply

October 8, 2023

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

September 20, 2023

MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

September 10, 2023

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

August 14, 2023

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

August 14, 2023

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

August 14, 2023

MediWound to Report Second Quarter 2023 Financial Results

August 6, 2023

MediWound Announces Commercial Launch of NexoBrid® in Japan

July 31, 2023

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

July 9, 2023

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

July 2, 2023

MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023

June 13, 2023

MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update

May 29, 2023

MediWound to Report First Quarter 2023 Financial Results

May 11, 2023

MediWound Announces an Additional $10 Million Award from BARDA

May 8, 2023

MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023

April 25, 2023

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

March 15, 2023

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

March 15, 2023

MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth

March 5, 2023

MediWound to Report Fourth Quarter and Year-End 2022 Financial Results

March 1, 2023

MediWound to Present Corporate Highlights at Upcoming Investor Conferences

February 22, 2023

MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares

February 6, 2023

MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market

February 2, 2023

Calls in 2023

Decks in 2023